Evidence map›Paper›PMID 42890084›Full record

ArticleTanaffos2025

Pericardiocentesis in Massive Pericardial Effusion in the Setting of Pulmonary Hypertension: Is It Beneficial?

Ahmad Mirdamadi, Mahsa Hashemirad, Shakiba Seifi

Abstract readCase Reports
In one paragraph

Article in Tanaffos, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ahmad MirdamadiDepartment of Cardiology, Najafabad Branch, Islamic Azad University, Najafabad, Isfahan, Iran.
Mahsa HashemiradFaculty of Medicine, Islamic Azad University, Najafabad Branch, Isfahan, Iran.
Shakiba SeifiNosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A serious complication of pulmonary hypertension (PH) is pericardial effusion (PE), which can significantly increase the mortality rate of affected patients. While managing this condition is critical, there is ongoing debate regarding the best therapeutic approaches. Although pericardiocentesis is mostly indicated in patients with cardiac tamponade, it may inadvertently increase mortality in the context of PH. Case Presentation: This case series reports on three patients who experienced PE associated with PH. Each patient received a different treatment, resulting in varying outcomes. One patient, unfortunately, died within 24 hours after undergoing pericardiocentesis. In contrast, the other two patients did not receive the procedure; instead, they were treated with medication. One of them has shown significant improvement after receiving more aggressive medical treatment. Both are alive with unremarkable limitations. Conclusion: The coexistence of pulmonary hypertension and massive pericardial effusion presents a complex challenge for management decisions. An effective approach requires a multidisciplinary strategy to optimize patient outcomes. While pericardiocentesis is essential in cases of massive pericardial effusion, it should be reconsidered if the underlying cause is pulmonary hypertension.

Indexed as

Cardiac TamponadeManagement GuidelinesMassive Pericardial EffusionPericardiocentesisPulmonary Hypertension

Identifiers

PMID42890084
PMCPMC13672038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.